|
China National Accord Medicines Corporation Ltd. (000028.SZ) Évaluation DCF
CN | Healthcare | Medical - Distribution | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
China National Accord Medicines Corporation Ltd. (000028.SZ) Bundle
Que vous soyez un investisseur ou un analyste, cette calculatrice DCF (000028SZ) est votre ressource incontournable pour une évaluation précise. Préchargé avec China National Accord Medicines Corporation Ltd. Données réelles, vous pouvez ajuster les prévisions et observer les effets en temps réel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52,045.8 | 59,649.5 | 68,357.8 | 73,443.1 | 75,477.5 | 80,002.0 | 84,797.6 | 89,880.8 | 95,268.7 | 100,979.5 |
| Revenue Growth, % | 0 | 14.61 | 14.6 | 7.44 | 2.77 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 |
| EBITDA | 2,757.2 | 3,295.1 | 3,401.5 | 3,762.3 | 4,032.0 | 4,202.1 | 4,454.0 | 4,721.0 | 5,004.0 | 5,304.0 |
| EBITDA, % | 5.3 | 5.52 | 4.98 | 5.12 | 5.34 | 5.25 | 5.25 | 5.25 | 5.25 | 5.25 |
| Depreciation | 927.1 | 1,194.0 | 1,431.0 | 1,487.7 | 1,589.2 | 1,601.3 | 1,697.2 | 1,799.0 | 1,906.8 | 2,021.1 |
| Depreciation, % | 1.78 | 2 | 2.09 | 2.03 | 2.11 | 2 | 2 | 2 | 2 | 2 |
| EBIT | 1,830.1 | 2,101.1 | 1,970.5 | 2,274.6 | 2,442.8 | 2,600.9 | 2,756.8 | 2,922.0 | 3,097.2 | 3,282.8 |
| EBIT, % | 3.52 | 3.52 | 2.88 | 3.1 | 3.24 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| Total Cash | 8,882.3 | 5,998.2 | 5,126.2 | 6,016.3 | 6,502.3 | 8,228.7 | 8,721.9 | 9,244.8 | 9,798.9 | 10,386.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 11,952.6 | 15,842.3 | 17,701.1 | 16,202.1 | 20,235.1 | 19,886.8 | 21,078.9 | 22,342.5 | 23,681.8 | 25,101.4 |
| Account Receivables, % | 22.97 | 26.56 | 25.89 | 22.06 | 26.81 | 24.86 | 24.86 | 24.86 | 24.86 | 24.86 |
| Inventories | 4,947.4 | 6,285.0 | 7,621.5 | 7,836.0 | 7,989.0 | 8,391.6 | 8,894.6 | 9,427.8 | 9,992.9 | 10,591.9 |
| Inventories, % | 9.51 | 10.54 | 11.15 | 10.67 | 10.58 | 10.49 | 10.49 | 10.49 | 10.49 | 10.49 |
| Accounts Payable | 12,259.7 | 15,217.6 | 16,717.9 | 15,233.0 | 7,545.1 | 16,682.2 | 17,682.3 | 18,742.2 | 19,865.7 | 21,056.5 |
| Accounts Payable, % | 23.56 | 25.51 | 24.46 | 20.74 | 10 | 20.85 | 20.85 | 20.85 | 20.85 | 20.85 |
| Capital Expenditure | -245.2 | -293.8 | -370.4 | -322.2 | -322.2 | -379.4 | -402.1 | -426.2 | -451.8 | -478.9 |
| Capital Expenditure, % | -0.47106 | -0.49259 | -0.5419 | -0.4387 | -0.42689 | -0.47423 | -0.47423 | -0.47423 | -0.47423 | -0.47423 |
| Tax Rate, % | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 | 35.34 |
| EBITAT | 1,253.1 | 1,365.4 | 1,333.5 | 1,463.2 | 1,579.6 | 1,717.2 | 1,820.1 | 1,929.3 | 2,044.9 | 2,167.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,705.3 | -3.6 | 699.0 | 2,428.4 | -9,027.4 | 12,022.0 | 2,420.1 | 2,565.2 | 2,719.0 | 2,882.0 |
| WACC, % | 4.71 | 4.63 | 4.69 | 4.62 | 4.63 | 4.66 | 4.66 | 4.66 | 4.66 | 4.66 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 20,496.1 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 2,968 | |||||||||
| Terminal Value | 179,141 | |||||||||
| Present Terminal Value | 142,677 | |||||||||
| Enterprise Value | 163,173 | |||||||||
| Net Debt | 7,250 | |||||||||
| Equity Value | 155,923 | |||||||||
| Diluted Shares Outstanding, MM | 557 | |||||||||
| Equity Value Per Share | 280.15 |
What You Will Receive
- Flexible Forecast Inputs: Modify key assumptions (growth %, margins, WACC) effortlessly to generate various scenarios.
- Real-Time Financial Data: Pre-loaded financial information for China National Accord Medicines Corporation Ltd. (000028SZ) to accelerate your analysis.
- Automated DCF Outputs: The template automatically determines Net Present Value (NPV) and intrinsic value.
- Customizable and Professional Design: A refined Excel model designed to fit your valuation requirements.
- Tailored for Analysts and Investors: Perfect for testing assumptions, validating strategies, and optimizing efficiency.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for China National Accord Medicines Corporation Ltd. (000028SZ).
- WACC Calculator: A pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to the healthcare sector.
- Customizable Forecast Assumptions: Easily alter growth projections, capital investments, and discount rates to fit your analysis needs.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to China National Accord Medicines Corporation Ltd. (000028SZ).
- Interactive Dashboard and Charts: Visual representations of essential valuation metrics for straightforward analysis and decision-making.
How It Operates
- Download the Template: Gain immediate access to the Excel-based China National Accord Medicines Corporation Ltd. (000028SZ) DCF Calculator.
- Enter Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Automatic Calculations: The model will refresh China National Accord Medicines Corporation Ltd.'s (000028SZ) intrinsic value in real-time.
- Test Various Scenarios: Experiment with different assumptions to see how they impact valuation.
- Analyze and Make Decisions: Leverage the findings to inform your investment strategies or financial assessments.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and consultants.
- Accurate Data: Historical and projected financials for China National Accord Medicines Corporation Ltd. (000028SZ) preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance makes the process simple and intuitive.
Who Can Benefit from This Product?
- Investors: Accurately assess the fair value of China National Accord Medicines Corporation Ltd. (000028SZ) prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and thorough analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Discover insights into financial modeling practices utilized by leading companies.
- Educators: Employ this resource as a teaching aid to illustrate various valuation methodologies.
Contents of the Template
- Pre-Filled Data: Contains historical financials and forecasts for China National Accord Medicines Corporation Ltd. (000028SZ).
- Discounted Cash Flow Model: An editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC using customized inputs.
- Key Financial Ratios: Evaluate the profitability, efficiency, and leverage of China National Accord Medicines Corporation Ltd. (000028SZ).
- Customizable Inputs: Easily adjust revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.